A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma

Blood

Volumn 105, Issue 8, 2005, Pages 3295-3302

  Li, Fu Jun ^a   Tsuyama, Naohiro ^a   Ishikawa, Hideaki ^a   Obata, Masanori ^a   Abroun, Saeid ^a   Liu, Shangqin ^a   Otsuyama, Ken Ichiro ^a   Zheng, Xu ^a   Ma, Zi ^a   Maki, Yasuko ^a   Kawano, Michio M ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; DEPHOSPHORYLATION; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPID RAFT; LYMPHOCYTE ACTIVATION; MYELOMA; PRIORITY JOURNAL;

EID: 20144388552     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-4083     Document Type: Article

References (47)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
2. Kawano MM, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature. 1988;322:83-85.
3. Klein B, Zhang X-G, Content J, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
4. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff M. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995; 182:243-248.
5. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labeling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol. 1996; 94:76-81.
6. + subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131-140.
7. Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood. 2002;99:2172-2178.
8. Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887-3897.
9. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol. 1994;12:85-116.
10. + thymocytes, and in B cell maturation. J Exp Med. 1996;183:1707-1718.
11. Kung C, Pingel JT, Heikinheimo M, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med. 2000;6:343-345.
12. Penninger JM, Irie-Sasaki J, Sasaki T, Oliveirados-Santos AJ. CD45: new jobs for an old acquaintance. Nat Immunol. 2001;2:389-396.
13. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003;21:107-137.
14. Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood. 1999;93: 1-14.
15. Justement LB, Campbell KS, Chien NC, Cambier JC. Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Science. 1991;252:1839-1842.
16. Hurley TR, Hyman R, Sefton BM. Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn, and c-src tyrosine protein kinases. Mol Cell Biol. 1993;13:1651-1656.
17. Yanagi S, Sugawara H, Kurosaki M, Sabe H, Yamamura H, Kurosaki T. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J Biol Chem. 1996;271:30487-30492.
18. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell. 2001; 106:403-411.
19. Janes PW, Ley SC, Magee AI. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol. 1999;147:447-461.
20. Weintraub BC, Jun JE, Bishop AC, Shokat KM, Thomas ML, Goodnow CC. Entry of B cell receptor into signaling domains is inhibited in tolerant B cells. J Exp Med. 2000;191:1443-1448.
21. Sehgal PB, Guo GG, Shah M, Kumar V, Patel K. Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem. 2002;277:12067-12074.
22. Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG, Brown DA. Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts: many raft proteins are acylated, while few are prenylated. J Biol Chem. 1999;274:3910-3917.
23. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity. 1998;8:723-732.
24. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med. 1999;190:1549-1560.
25. Parolini I, Sargiacomo M, Lisanti MP, Peschle C. Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Tritonin-soluble plasma membrane domains of human leukemic cell lines and normal granulocytes. Blood. 1996;87:3783-3794.
26. Edmonds SD, Ostergaard HL. Dynamic association of CD45 with detergent-insoluble microdomains in T lymphocytes. J Immunol. 2002;169: 5036-5042.
27. Gupta N, DeFranco AL. Visualizing lipid raft dynamics and early signaling events during antigen receptor-mediated B-lymphocyte activation. Mol Biol Cell. 2003;14:432-444.
28. Novak TJ, Farber D, Leitenberg D, Hong SC, Johnson P, Bottomly K. Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity. 1994;1: 109-119.
29. Chui D, Ong CJ, Johnson P, Teh HS, Marth JD. Specific CD45 isoforms differentially regulate T cell receptor signaling. EMBO J. 1994;13:798-807.
30. Leitenberg D, Novak TJ, Farber D, Smith BR, Bottomly K. The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. J Exp Med. 1996;183:249-259.
31. Dornan S, Sebestyen Z, Gamble J, et al. Differential association of CD45 isoforms with CD4 and CD8 regulates the actions of specific pools of p56lck tyrosine kinase in T cell antigen receptor signal transduction. J Biol Chem. 2002;277:1912-1918.
32. Abroun S, Ishikawa H, Tsuyama N, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor alpha myeloma cells. Blood. 2004;103:2291-2298.
33. Vidalain PO, Azocar O, Servet-Delprat C, Rabourdin-Combe C, Gerlier D, Manie S. CD40 signaling in human dendritic cells is initiated within membrane rafts. EMBO J. 2000;19:3304-3313.
34. - monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood. 1991;78: 711-719.
35. Schneider U, Van Lessen A, Huhn D, Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol. 1997;97:56-64.
36. Morrow IC, Rea S, Martin S, et al. Flotillin-1/reggie-2 traffics to surface raft domains via a novel golgi-independent pathway: identification of a novel membrane targeting domain and a role for palmitoylation. J Biol Chem. 2002;277:48834-48841.
37. Kawabuchi M, Satomi Y, Takao T, et al. Transmembrane phosphoprotein Csk regulates the activities of Src-family tyrosine kinases. Nature. 2000;404:999-1003.
38. Brdicka T, Pavlistova D, Leo A, et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med. 2000; 191:1591-1604.
39. Amano M, Galvan M, He J, Baum LG. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem. 2003; 278:7469-7475.
40. Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science. 1998;279:88-91.
41. Xu Z, Weiss A. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol. 2002;3:764-771.
42. Ten Dam GB, Zilch CF, Wallace D, et al. Regulation of alternative splicing of CD45 by antagonistic effects of SR protein splicing factors. J Immunol. 2000;164:5287-5295.
43. Wang HY, Xu X, Ding JH, Bermingham JR, Fu XD. SC35 plays a role in T cell development and alternative splicing of CD45. Mol Cell. 2001;7: 331-342.
44. Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A. Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol. 2003;23:2017-2028.
45. Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature. 2001;409:349-354.
46. Rajendran L, Masilamani M, Solomon S, et al. Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells. Proc Natl Acad Sci U S A. 2003;100:8241-8246.
47. Wulf GG, Luo KL, Goodell MA, Brenner MK. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood. 2003;101:2434-2439.